alfuzosin (Rx)

Brand and Other Names:Alfutral, UroXatral, more...Xatral
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet, extended release

  • 10mg
more...

Benign Prostatic Hyperplasia (BPH)

10 mg PO qDay taken after same meal

Safety & efficacy not established

Next:

Interactions

Interaction Checker

and alfuzosin

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            1-10%

            Abdominal pain (1-2%)

            Back pain (1-2%)

            Brochitis (1-2%)

            Constipation (1-2%)

            Dizziness (5.7%)

            Dyspepsia (1-2%)

            Fatigue (2.7%)

            Headache (3%)

            Impotence (1-2%)

            Nausea (1-2%)

            Pharyngitis (1-2%)

            URT infection (3%)

            Sinusitis (1-2%)

            Upper respiratory infection (3%)

            Postmarketing Reports

            General disorders: Edema

            Cardiac disorders: Tachycardia, chest pain, angina pectoris in patients with pre-existing coronary artery disease, atrial fibrillation

            Gastrointestinal disorders: Diarrhea, vomiting

            Hepatobiliary disorders: Hepatocellular and cholestatic liver injury (including cases with jaundice leading to drug discontinuation)

            Upper respiratory system: Rhinitis

            Reproductive system: Priapism

            Dermatology: Rash, pruritus, urticaria, angioedema, toxic epidermal necrolysis

            Vascular disorders: Flushing

            Blood and lymphatic system disorders: Thrombocytopenia

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity

            Moderate to severe liver impairment

            Coadministration with potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir) or other alpha1-blocking agents

            Cautions

            Caution in coronary artery disease, liver disease, symptomatic orthostatic hypotension or coadministration with other drugs that lower blood pressure

            May cause syncope (first-dose effect)

            Discontinue treatment if angina occurs or worsens

            Rule out prostate cancer before initiating therapy (symptoms similar)

            Priapism may occur with use

            Rule out prostate cancer prior to treatment

            Caution with renal impairment (ieg, CrCl <30 mL/min)

            Caution with history of prolonged QT syndrome (shown to prolong QT interval)

            Intraoperative floppy iris syndrome during cataract surgery reported Advise patient regarding risk of priapism

            Do not chew or crush tablets

            Not for use as antihypertensive drug

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: B

            Lactation: Not indicated for use in women

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Selective antagonist of postsynaptic alpha-1-adrenoceptors; blockade of adrenoreceptors in the prostate, prostatic capsule, bladder neck and prostatic urethra

            Absorption

            Bioavailability: 49%

            Peak Plasma Time: 8 hr

            Peak Plasma Concentration: 13.6 ng/mL

            AUC: 194 ng.hr/mL

            Distribution

            Protein Bound: 82-90%

            Vd: 3.2 L/kg

            Metabolism

            Hepatic P450 enzyme CYP3A4

            Elimination

            Half-life: 5-10 hr

            Excretion: Feces (69%); urine (24%)

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.